BioVeda
Home
Investment Policy
People
Investors
Our Companies
Our CEOs
News and Events
2009 News
2008 News
Contact
2008 News
Dec 19
-
Dynavax Announces Termination of Partnership With Merck for HEPLISAV Hepatitis B Vaccine
Dec 17
- GlaxoSmithKline and Dynavax Announce Worldwide Strategic Alliance
Dec 11
- Renovo Announces Positive Juvista Phase 2 Results, Commencement of European Phase 3 Trial and Zeesteem Results
Dec 8
- Kiadis Pharma receives two orphan drug designations for Reviroc from the FDA
Dec 8
-
Dynavax Presents Preclinical Data Supporting Its Novel Universal Flu Vaccine Candidate
Dec 4
- Kiadis Pharma announces positive clinical results for ATIR in mismatched bone marrow transplantations - Kiadis Pharma proceeds with pivotal trial ATIR
Nov 25
- Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals
Oct 26
-
Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Oct 21
- Dynavax and Merck & Co., Inc. Provide Update on U.S. FDA Clinical Hold on Investigational Vaccine HEPLISAV
Sep 29
- Dynavax Awarded $17 Million Contract from National Institutes of Health
Sep 22
- EMEA grants Kiadis Pharma lead product ATIR orphan drug designation
Sep 22
- Dynavax Receives $4.5 Million Milestone from AstraZeneca
May 29
- Renovo Directors Purchase Shares
May 16
- Dynavax TOLAMBA Chamber Study Misses Primary Endpoint; Company Updates 2008 Financial Outlook
May 2
-
Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals' Nicotinic Alpha-7 Agonist, MEM 3454
Apr 17
- 12 Month Analysis of Juvista Clinical Trials 0050 & 0036
Apr 17
- Dynavax and Merck & Co., Inc. Update Status of Clinical Hold of Investigational Vaccine HEPLISAV
Apr 16
-
Paratek Pharmaceuticals Completes $40 Million Private Placement to Finance Clinical Programs Including Oral Antibiotic to Combat MRSA and Other Infections
Mar 17
- Dynavax and Merck & Co., Inc. Report Clinical Hold of Investigational Vaccine HEPLISAV
Mar 3
- Juvista Phase II Trial Results in Scar Revision and Breast Augmentation Surgery
Feb 25
- Dynavax Names Martin E. Sanders, M.D. Executive Vice President, Chief Development Officer
Feb 22
- Kiadis Pharma obtains FDA approval to start a phase III clinical trial for Reviroc™ in the United States. FDA approves IND application for Reviroc
Feb 19
-
Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
Feb 7
-
Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer
Jan 31
- Kiadis Pharma announces successful completion of Rhitol™ Phase II clinical study
Your Partner in Asia